Trial
NCT03234465
Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Oragenics, Inc.
Collaborators
—
Condition
Oral Mucositis
Intervention
AG013
Why stopped
No efficacy could be demonstrated, sponsor decided to prematurely end the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-23